Explore

Rapid ReadRapid Read
Review Highlights AI's Transformative Potential and Persistent Challenges in Pharmaceutical Development

Review Highlights AI's Transformative Potential and Persistent Challenges in Pharmaceutical Development

A comprehensive review published in Discover Pharmaceutical Sciences by Shashi Kant, Deepika, and Saheli Roy evaluates the extensive application of artificial intelligence (AI) tools across pharmaceutical discovery and development. The review details how multidisciplinary AI systems, including machine learning, deep learning, natural language processing, and generative models, are being used to overcome historical bottlenecks in target validation, compound screening, structural optimization, and clinical investigation. AI algorithms are shown to optimize protocols, select endpoints, refine statistical power calculations, and assist patient recruitment in clinical trials. Companies like Exscientia have already advanced AI-designed molecules into human trials. However, the review also emphasizes significant limitations, such as the scarcity of high-quality, standardized training data, the risk of systemic biases in historical datasets, and the 'black box' nature of many deep neural networks, which complicate...
TrendlineTrendline
Merck Announces Positive Phase 2b Results for Efinopegdutide in MASH with Fibrosis

Merck Announces Positive Phase 2b Results for Efinopegdutide in MASH with Fibrosis

Merck Announces Positive Phase 2b Results for Efinopegdutide in MASH with Fibrosis
TrendlineTrendline
Immunome Reports Strong Q3 2026 Financial Results and Advances Oncology Pipeline with New Clinical Trials

Immunome Reports Strong Q3 2026 Financial Results and Advances Oncology Pipeline with New Clinical Trials

Immunome Reports Strong Q3 2026 Financial Results and Advances Oncology Pipeline with New Clinical Trials
Rapid ReadRapid Read
AI Integration in Clinical Trials Raises Significant Data Security Concerns for Healthcare and Biotech Sectors

AI Integration in Clinical Trials Raises Significant Data Security Concerns for Healthcare and Biotech Sectors

The increasing integration of Artificial Intelligence (AI) in healthcare and biotech research, particularly within clinical trials, is introducing new and complex data security challenges. While AI is becoming an expected part of daily operations, with 75% of U.S. health systems using at least one AI application, it also creates additional vulnerabilities for sensitive patient records and proprietary research data. Healthcare remains a prime target for cybercriminals, with the average data breach costing $7.42 million and taking 279 days to identify and contain. The 2024 Change Healthcare ransomware attack, which affected 192.7 million individuals due to a single missing control, highlights the severe consequences of security lapses. AI models and their training datasets are now valuable targets for attackers, necessitating robust data protection strategies that extend to every model, dataset, and environment involved in clinical trial information. The FDA and EMA have jointly released ten guiding principl...
Rapid ReadRapid Read
GeneSPOT Computational Framework Introduced to Map Spatial Gene Relationships and Dynamics in Tissues

GeneSPOT Computational Framework Introduced to Map Spatial Gene Relationships and Dynamics in Tissues

Researchers have developed Gene SPatial Optimal Transport, or GeneSPOT, a new computational framework designed to characterize the spatial relationships among genes and quantify their reorganization across various biological conditions and over time. Published in Nature Methods, this gene-centric analytical framework complements existing cell-centric methods by mapping how the relational spatial organization of molecular features changes within tissues. While current spatial omics technologies primarily focus on identifying cellular states and differentially expressed molecular features, GeneSPOT extends this by evaluating spatial arrangements beyond individual cellular states. The framework has successfully resolved tissue structures in diverse applications, including validation analyses in the mouse brain, where it captured biologically meaningful spatial gene programs and identified organized molecular patterns within complex tissue architecture.
TrendlineTrendline
101 Therapeutics Presents Macrophage-Targeted Glucocorticoid 101-PGC-005 Data at ACR Convergence 2026

101 Therapeutics Presents Macrophage-Targeted Glucocorticoid 101-PGC-005 Data at ACR Convergence 2026

101 Therapeutics Presents Macrophage-Targeted Glucocorticoid 101-PGC-005 Data at ACR Convergence 2026
Rapid ReadRapid Read
Acadia Pharmaceuticals to Present Remlifanserin Data at Alzheimer's Disease Conference

Acadia Pharmaceuticals to Present Remlifanserin Data at Alzheimer's Disease Conference

Acadia Pharmaceuticals Inc. announced it will present two data presentations related to Alzheimer's disease psychosis (ADP) and its investigational drug, remlifanserin, at the 2026 Clinical Trials on Alzheimer's Disease (CTAD) conference in Boston. The presentations will include findings from the Phase 2 portion of the ongoing RADIANT clinical trial program, which evaluates remlifanserin in patients with ADP. An oral presentation will detail the efficacy and safety of remlifanserin, while a poster presentation will examine biomarker heterogeneity among patients meeting clinical criteria for ADP. Remlifanserin is a novel, highly selective 5-HT2A receptor inverse agonist being developed to treat psychosis associated with Alzheimer's disease and Lewy body dementia. Currently, there is no FDA-approved drug specifically for the treatment of Alzheimer's disease psychosis.
Rapid ReadRapid Read
U.S. FDA Approves 16 New Personalized Therapies for Rare Diseases in 2023, Signaling Growth in Precision Medicine

U.S. FDA Approves 16 New Personalized Therapies for Rare Diseases in 2023, Signaling Growth in Precision Medicine

The U.S. Food and Drug Administration (FDA) approved 16 new personalized treatments for rare diseases in 2023, a significant increase from six approvals in 2022. This surge in approvals highlights a growing trend towards personalized medicine, which tailors treatments to individual patients based on their unique genetic characteristics, disease susceptibility, and predicted drug response. Beyond rare diseases, the 2023 approvals also included seven cancer therapies and three treatments for other conditions. This shift is driving the demand for genome annotation services, which convert raw genetic data into clinically actionable information to guide diagnosis, treatment selection, and therapeutic development. The global genome annotation services market is projected to reach $2.75 billion by 2030, growing at a compound annual growth rate (CAGR) of 13.9%. Key drivers for this growth include increased demand for personalized medicine research, the adoption of AI-powered bioinformatics platforms, and stronger ...
Rapid ReadRapid Read
FDA Proposes New Guidance to Accelerate Gene Therapies for Rare Diseases

FDA Proposes New Guidance to Accelerate Gene Therapies for Rare Diseases

The U.S. Food and Drug Administration (FDA) is shaping new guidance that could significantly speed up the development of gene therapies for rare diseases. This initiative, influenced by scientists in Philadelphia, aims to allow researchers to test a gene therapy platform against a sample of mutations. If successful, this would enable customization for individual patients without requiring a new clinical trial for each specific mutation. The FDA's new Rare Disease Framework Initiative emphasizes integrating patient perspectives early in the drug development cycle, moving away from traditional late-stage feedback. This framework champions the use of cutting-edge science, novel methods, and innovative clinical trial designs, including externally controlled studies, particularly for ultrarare diseases affecting fewer than 1,000 individuals. Under the Rare Disease Evidence Principles (RDEP) program, treatments for these ultrarare conditions may only need evidence from a single-arm trial, supplemented by strong ...
Rapid ReadRapid Read
AI Automation Reshapes Clinical Data Management Amidst EDC Market Growth

AI Automation Reshapes Clinical Data Management Amidst EDC Market Growth

The clinical data management sector is undergoing a significant transformation due to the integration of AI automation. Clinical data managers, who traditionally manually wrote queries, are now observing AI automatically drafting these queries, a shift occurring faster than many trial teams anticipated. This change is a central topic of discussion at an eClinical Solutions panel on AI in data management, which aims to explore how AI is redefining data review and interpretation. The panel also addresses the essential human expertise that AI systems cannot replicate. Major Electronic Data Capture (EDC) platforms have started incorporating AI features to automate repetitive configuration tasks. However, the effectiveness of these features with complex, real-world trial data remains a key area of evaluation. Human oversight is still crucial for reviewing flagged anomalies, protocol deviations, and inconsistencies across sites, as this requires judgment based on practical experience.
Rapid ReadRapid Read
University of Pittsburgh Professor Develops AI Framework for Drug Discovery

University of Pittsburgh Professor Develops AI Framework for Drug Discovery

Junmei Wang, a professor of pharmaceutical sciences at the University of Pittsburgh, has developed a new generative AI framework called Full-Spectrum Generative Lead Discovery (FSGLD). This framework, detailed in a paper published in the journal Science Advances on October 28, utilizes generative AI to screen existing compounds for potential therapeutic applications. Unlike traditional AI methods that often focus on generating new, potentially unsynthesizable molecules, FSGLD identifies real, existing compounds that can bind to target receptors. The system employs a general adversarial network (GAN) called DRUG-GAN, which learns to generate molecular fingerprints. These AI-generated patterns then guide researchers in searching chemical databases for existing molecules with similar characteristics. Wang's lab successfully used this method to screen for compounds linked to G protein-coupled receptors (GPCRs) and protein kinase, two commonly targeted drug receptors, identifying novel compounds that effectivel...
TrendlineTrendline
3billion and DeepLife Announce AI Drug Discovery Collaboration to Enhance Therapeutic Target Identification

3billion and DeepLife Announce AI Drug Discovery Collaboration to Enhance Therapeutic Target Identification

3billion and DeepLife Announce AI Drug Discovery Collaboration to Enhance Therapeutic Target Identification